## (FILE 'HOME' ENTERED AT 16:44:43 ON 11 FEB 2006)

## FILE 'REGISTRY' ENTERED AT 16:44:49 ON 11 FEB 2006

E "DILTIAZEM"/CN 25

L1 1 S E3

E "DILTIAZEM"/CN 25

E "CINNARIZINE"/CN 25

L2 1 S E3

E "NIFEDIPINE"/CN 25

L3 1 S E3

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 42399-41-7 REGISTRY

CN 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)-OTHER NAMES:

CN (+)-cis-Diltiazem

CN (+)-Diltiazem

CN Adizem XL

CN Cartia XT

CN Coras

...... 🧎

CN d-cis-Diltiazem

CN d-Diltiazem

CN Diltiazem

CN Dilzem

FS STEREOSEARCH

MF C22 H26 N2 O4 S

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIUDB, IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK\*, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

- DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
- RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
- RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
- RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
- RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); USES (Uses)

Absolute stereochemistry. Rotation (+).

- 4662 REFERENCES IN FILE CA (1907 TO DATE)
- 69 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 4665 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN
     298-57-7 REGISTRY
CN
     Piperazine, 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)- (9CI) (CA INDEX
     NAME)
OTHER CA INDEX NAMES:
     Piperazine, 1-cinnamyl-4-(diphenylmethyl)- (6CI, 7CI, 8CI)
OTHER NAMES:
CN
     1-(3-Phenylallyl)-4-(diphenylmethyl)piperazine
CN
     1-Benzhydryl-4-cinnamylpiperazine
CN
     1-Cinnamyl-4-(diphenylmethyl)piperazine
CN
     1-Cinnamyl-4-benzhydrylpiperazine
     1-Diphenylmethyl-4-cinnamoylpiperazine
CN
CN
     516MD
CN
     Aplactan
CN
     Aplexal
CN
     Apotomin
CN
     Artate
CN
     Carecin
CN
     Cerebolan
CN
     Cerepar
CN
     Cinaperazine
CN
     Cinazyn
CN
     Cinnacet
CN
     Cinnageron
CN
     Cinnarizine
CN
     Cinnipirine
CN
     Corathiem
     Denapol
CN
CN
     Dimitron
CN
     Dimitronal
CN
     Eglen
CN
     Folcodal
     Giganten
CN
CN
     Glanil
CN
     Hilactan
CN
     Ixterol
CN
     Katoseran
CN
     Labyrin
CN
     Lazeta
CN
     Marisan
CN
     Midronal
CN
     Mitronal
CN
     N-Benzhydryl-N'-cinnamylpiperazine
CN
     Olamin
CN
     Processine
CN
     R 1575
CN
     R 516
CN
     Sedatromin
CN
     Sepan
CN
     Siptazin
CN
     Spaderizine
CN
     Stugeron
CN
     Stutgeron
CN
     Stutgin
CN
     Toliman
FS
     3D CONCORD
MF
     C26 H28 N2
CI
     COM
SR
LC
                   ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
     STN Files:
       CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, PROMT,
```

PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN,

USPAT2, USPATFULL

مه خو سرچ

(\*File contains numerically searchable property data)
Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

- DT.CA CAplus document type: Book; Conference; Journal; Patent; Report
- RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
   PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
- RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
- RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

CH2 -- CH -- CH -- Ph

N N

CHPh<sub>2</sub>

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

735 REFERENCES IN FILE CA (1907 TO DATE)

- 23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 735 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- 13 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
L3
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN
   21829-25-4 REGISTRY
CN
     3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-
     , dimethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
     3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-
     , dimethyl ester (8CI)
OTHER NAMES:
     2,6-Dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydropyridine
     2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid
     dimethyl ester
CN
     4-(2-Nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine
CN
     Adalat
CN
     Adalat 10
CN
     Adalat 20
CN
     Adalat 5
CN
     Adalat CC
CN
    Adalat CR
CN
    Adalat Crono
CN
    Adalat FT
CN
    Adalat GITS
CN
     Adalat GITS 30
CN
     Adalat LA
CN
     Adalat LP
CN
     Adalat Oros
CN
     Adalat PA
CN
     Adalat Retard
CN
     Adalate
CN
     Adapine
CN
     Adapress
CN
     Alat
CN
     Aldipin
CN
     Alfadat
CN
     Alonix
CN
     Alonix S
CN
     Alpha-Nifedipine Retard
CN
     Angipec
CN
     Anifed
CN
     Anpine
CN
     Apo-Nifed
CN
     Aprical
CN
     BAY 1040
CN
     BAY-a 1040
CN
    Bonacid
CN
    Calcibloc
CN
    Calcigard
CN
    Calcilat
CN
    Camont
CN
    Cardifen
CN
     Cardilat
CN
     Cardilate
CN
     Cardionorm
CN
     Chronadalate
     Chronadalate LP
CN
CN
     Citilat
CN
     Coracten
CN
     Coral
CN
     Cordafen
CN
    Nifedipine
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
     DISPLAY
```

J. 2 12

FS

DR MF 3D CONCORD

C17 H18 N2 O6

11104-22-6, 101539-70-2, 101554-38-5


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)
ther Sources: DSL\*\*, EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

- DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent; Report
- RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
  MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP
  (Properties); RACT (Reactant or reagent); USES (Uses)
- RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
- RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
- RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7627 REFERENCES IN FILE CA (1907 TO DATE)
105 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7634 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:168901 CAPLUS

DOCUMENT NUMBER: 141:199402

TITLE: Screening of bioadhesive materials for oral

sustained-release diltiazem

AUTHOR(S): Li, Yunchun; Fu, Jie; Zhang, Zhirong; Yang, Xiaochuan CORPORATE SOURCE: Department of Nuclear Medicine, West China Hospital of

Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, 610041, Peop. Rep. China

SOURCE: Zhonghua Heyixue Zazhi (2002), 22(6), 376-378

CODEN: CITCDE; ISSN: 0253-9780

PUBLISHER: Jiangsusheng Yuanzi Yixue Yanjiuso

DOCUMENT TYPE: Journal LANGUAGE: Chinese

TI Screening of bioadhesive materials for oral sustained-release diltiazem

AU Li, Yunchun; Fu, Jie; Zhang, Zhirong; Yang, Xiaochuan

AB The bioadhesive materials for oral sustained-release diltiazem was screened. The bioadhesion force of adhesive hydroxypropylmethylcellulose (HPMC) polymer, carbomers (Cb), PVPk30 and CMCNa with rat gastric and intestinal mucosa and the excretion rate of the adhesives in gastrointestinal tract of rats were measured to screen the best

bioadhesive material. The bioadhesive ability of the

best bioadhesive material was tested in

gastrointestinal tract of dogs with in vivo radionuclide tracing imaging. The bioadhesion force of Cb with rat intestinal mucosa (19.6 - 31.0 g) was bigger than that of other materials (4.0 - 24.3 g), and the excretion rate of Cb934 was the slowest in gastrointestinal tract of rats. The Cb934 remarkably increased the retention time of its preparation in the gastrointestinal tract of dogs. Cb934 can be used as bioadhesive material of oral sustained-release medicine.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:434091 CAPLUS

DOCUMENT NUMBER: 122:222710

TITLE: Liposomes-based nasal delivery system of nifedipine:

Development and characterization

AUTHOR(S): Vyas, S. P.; Goswami, S. K.; Singh, Ranjit

CORPORATE SOURCE: Pharmaceutics Laboratory, Department of Pharmaceutical

Sciences, Dr H.S. Gour Vishwavidyalaya, Sagar (M.P.),

470 003, India

SOURCE: International Journal of Pharmaceutics (1995), 118(1),

23-30

CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier DOCUMENT TYPE: Journal LANGUAGE: English

TI Liposomes-based nasal delivery system of nifedipine: Development and

characterization

AU Vyas, S. P.; Goswami, S. K.; Singh, Ranjit

AB Multilamellar liposomes bearing nifedipine were prepared using a conventional cast film method. The prepared liposomes were evaluated for release characteristics, in vitro, in situ bioadhesion and in vivo absorption following nasal administration. Charged components, stearylamine, dicetyl phosphate and some fusogenic/bioadhesive material were also incorporated into the liposomes. It was observed that pos. charged liposomes possessed maximum bioadhesion while lysophosphatidylcholine liposomes showed considerable bioadhesion. In vivo expts. revealed that the nasal administration of liposomes eliminated hepatic first-pass metabolism and could maintain an effective drug

concentration for

prolonged periods of time with improved bioavailability.

## (FILE 'HOME' ENTERED AT 16:27:29 ON 11 FEB 2006)

	FILE	'CAPLUS' ENTERED AT 16:27:42 ON 11 FEB 2006
L1		4717 S CALCIUM (W) CHANNEL (W) BLOCKER
L2		1584 S L1 AND (DILTIAZEM OR CINNARIZINE OR NIFEDIPINE)
L3		15 S L2 AND (PERMEATION (W) ENHANCER) OR (BIOADHESIVE (W) MATERIAL
L4		15 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)
L5		14 S L2 AND (CONTROLLED OR TIMED OR DELAYED) (W) RELEASE